Lactobacillus rhamnosus, LGG®
- the world’s most documented probiotic strain
The LGG® strain has been investigated in numerous clinical studies and has been associated with improvements health benefits, including gastrointestinal and immune function
Extensive clinical investigation of the LGG® strain
The LGG® strain has been used worldwide since 1990 as an ingredient in food and dietary supplements, with no known adverse events. It has been extensively studied; the LGG® strain has been described in more than 250 publications of human clinical trials. The strain has been studied across various health areas, in newborns,1 preterm infants,2 children,3, 4, 5 pregnant women,6, 7 adults,8 and in the elderly,9 with no known reported adverse events.
LGG® from Chr. Hansen has in clinical studies been associated with numerous health benefits in various populations
In children, some of the health areas with the most clinical evidence on LGG® are:
LGG® has been associated with faster normalization of stool consistency,10 and shortened duration of acute diarrhea.5, 10, 11
LGG® has been associated with reduced incidence of antibiotic-associated diarrhea.1, 3
LGG® has been associated with a reduced incidence of gastrointestinal,4 and respiratory tract infections.4
LGG® has been associated with a reduced incidence of respiratory infections,4, 12 a decrease in the number of respiratory infections lasting more than three days4, 12 and a significantly lower number of days with respiratory symptoms.12
LGG® has been associated with a decreased risk of dental caries based on a clinical evaluation and a microbiological analysis,13 and lower Streptococcus mutans levels from dental plaque and saliva.14
In adults, some of the health areas with the most clinical evidence on LGG® are:
LGG® has been associated with a reduction in the incidence of acute diarrhea during travel to high-risk areas.8
A significant increase in vaccine-specific antibodies has been observed following the introduction of LGG®, suggesting its important potential as an adjuvant to support influenza vaccine immunogenicity.15
LGG® is safe for human consumption and has been granted QPS (Qualified Presumption of Safety) status in Europe16 and been the subject of a GRAS (Generally Recognized As Safe) notice to the US Food and Drug Administration,17 with no adverse events.
LGG® is a registered trademark of Chr. Hansen A/S.
The article is provided for informational purposes regarding probiotics and is not meant to suggest that any substance referenced in the article is intended to diagnose, cure, mitigate, treat, or prevent any disease.
At Chr. Hansen, our strains are backed by science. All of our probiotic strains are supported by clinical documentation. Learn more about the beneficial effects our strains have on different health areas.
References Open Close
2. Underwood MA, et al. A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. J Pediatr Gastroenterol Nutr. 2009;48(2):216-25. (PubMed)
3. Vanderhoof JA, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. The Journal of Pediatrics. 1999;135(5):564-8.(PubMed)
4. Hojsak I, et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics. 2010;125(5):e1171-7.(PubMed)
5. Isolauri E, et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991;88(1):90-7.(PubMed)
6. Gueimonde M, et al. Effect of maternal consumption of lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr. 2006;42(2):166-70.(PubMed)
7. Lahtinen SJ, et al. Prenatal probiotic administration can influence Bifidobacterium microbiota development in infants at high risk of allergy. J Allergy Clin Immunol. 2009;123(2):499-501.(PubMed)
8. Hilton E, et al. Efficacy of Lactobacillus GG as a Diarrheal Preventive in Travelers. J Travel Med. 1997;4(1):41-3.(PubMed)
9. Hatakka K, et al. Probiotics reduce the prevalence of oral candida in the elderly--a randomized controlled trial. J Dent Res. 2007;86(2):125-30.(PubMed)
10. Aggarwal S, et al. Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled, randomized controlled trial. Indian J Med Res. 2014;139(3):379-85.(PubMed)
11. Sindhu KNC, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(8):1107-15.(PubMed)
12. Hojsak I, et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2010;29(3):312-6.(PubMed)
13. Nase L, et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35(6):412-20.(PubMed)
14. Glavina D, et al. Effect of LGG yoghurt on Streptococcus mutans and Lactobacillus spp. salivary counts in children. Coll Antropol. 2012;36(1):129-32.(PubMed)
15. Davidson LE, et al. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr. 2011;65(4):501-7.(PubMed)
16. EFSA Panel on Biological Hazards (BIOHAZ). Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 3: Suitability of taxonomic units notified to EFSA until September 2015. EFSA Journal. 2015;13:4331
17. Food and Drug Administration. GRAS Notice Inventory > Agency Response Letter. GRAS Notice No GRN 000049. 2002